Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (401-410 of 692) with videos related to

Pageof 70
Sort By:
Molecular Cancer Therapeutics|January 16, 2007
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferationDeborah L Marrocco, Wayne D Tilley, Tina Bianco-Miotto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 17, 2008
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapyNeeta Pandit-Taskar, Joseph A O'Donoghue, Michael J Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapyEthan Basch, Alexia Iasonos, Allison Barz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancerDaniel C Danila, Glenn Heller, Gretchen A Gignac, et al.
Urologic Oncology|January 14, 2011
Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostateC N Papandreou, T Bogenrieder, C L Finstad, et al.
Cancer|July 17, 2015
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implicationsDana E Rathkopf, Steven M Larson, Aseem Anand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumorsJulie L Eiseman, Jianxia Guo, Ramesh K Ramanathan, et al.
Neurology|March 10, 2015
Ictal adipokines are associated with pain severity and treatment response in episodic migraineNu Cindy Chai, Bizu Gelaye, Gretchen E Tietjen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancerA D Seidman, H I Scher, J L Gabrilove, et al.
Journal of Pain and Symptom Management|August 9, 2021
Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes DataBlake Langlais, Gina L Mazza, Gita Thanarajasingam, et al.
Pageof 70

Showing results (401-410 of 692) with videos related to

Sort By:
Pageof 70
Molecular Cancer Therapeutics|January 16, 2007
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferationDeborah L Marrocco, Wayne D Tilley, Tina Bianco-Miotto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 17, 2008
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapyNeeta Pandit-Taskar, Joseph A O'Donoghue, Michael J Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapyEthan Basch, Alexia Iasonos, Allison Barz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancerDaniel C Danila, Glenn Heller, Gretchen A Gignac, et al.
Urologic Oncology|January 14, 2011
Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostateC N Papandreou, T Bogenrieder, C L Finstad, et al.
Cancer|July 17, 2015
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implicationsDana E Rathkopf, Steven M Larson, Aseem Anand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumorsJulie L Eiseman, Jianxia Guo, Ramesh K Ramanathan, et al.
Neurology|March 10, 2015
Ictal adipokines are associated with pain severity and treatment response in episodic migraineNu Cindy Chai, Bizu Gelaye, Gretchen E Tietjen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancerA D Seidman, H I Scher, J L Gabrilove, et al.
Journal of Pain and Symptom Management|August 9, 2021
Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes DataBlake Langlais, Gina L Mazza, Gita Thanarajasingam, et al.
Pageof 70